Medigene Ag (MDGEF) 7.5300 $MDGEF Basal Cell Carcinoma

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Medigene Ag (MDGEF) 7.5300 $MDGEF

Basal Cell Carcinoma (Basal Cell Epithelioma) Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/hq8dm9/basal_cell) has announced the addition of the "Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Basal Cell Carcinoma Basal Cell Epithelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Basal Cell Carcinoma Basal Cell Epithelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Basal Cell Carcinoma Basal Cell Epithelioma Overview - Therapeutics Development - Pipeline Products for Basal Cell Carcinoma Basal Cell Epithelioma - Overview - Pipeline Products for Basal Cell Carcinoma Basal Cell Epithelioma - Comparative Analysis - Basal Cell Carcinoma Basal Cell Epithelioma - Therapeutics under Development by Companies - Basal Cell Carcinoma Basal Cell Epithelioma - Therapeutics under Investigation by Universities/Institutes - Basal Cell Carcinoma Basal Cell Epithelioma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Basal Cell Carcinoma Basal Cell Epithelioma - Products under Development by Companies - Basal Cell Carcinoma Basal Cell Epithelioma - Products under Investigation by Universities/Institutes - Basal Cell Carcinoma Basal Cell Epithelioma - Companies Involved in Therapeutics Development - 4SC AG - Biofrontera AG - Biosceptre (Aust) Pty Ltd - Genextra S.p.a. - Ignyta, Inc. - Laboratories Ojer Pharma S.L. - MediGene AG - Novartis AG - Redx Pharma Plc - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Transgene SA For more information visit http://www.researchandmarkets.com/research/hq8dm9/basal_cell
RXDX: 5.66 (-0.13), NVS: 79.64 (+0.33)

Global Genital Warts (Condylomata Acuminata) Therapeutics Pipeline Review, H2 2015
M2 - Mon Jan 18, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/ppm8zf/genital_warts) has announced the addition of the "Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Warts (Condylomata Acuminata), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Warts (Condylomata Acuminata) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Genital Warts (Condylomata Acuminata) Overview - Therapeutics Development - Pipeline Products for Genital Warts (Condylomata Acuminata) - Overview - Pipeline Products for Genital Warts (Condylomata Acuminata) - Comparative Analysis - Genital Warts (Condylomata Acuminata) - Therapeutics under Development by Companies - Genital Warts (Condylomata Acuminata) - Therapeutics under Investigation by Universities/Institutes - Genital Warts (Condylomata Acuminata) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Genital Warts (Condylomata Acuminata) - Products under Development by Companies - Genital Warts (Condylomata Acuminata) - Products under Investigation by Universities/Institutes - Genital Warts (Condylomata Acuminata) - Companies Involved in Therapeutics Development - Agilvax, Inc. - Biogenomics Limited - BioMAS Ltd. - Biota Pharmaceuticals, Inc. - Foamix Pharmaceuticals Ltd. - G&E Herbal Biotechnology Co., Ltd. - Helix BioPharma Corp. - Laboratories Ojer Pharma S.L. - LEO Pharma A/S - MediGene AG - NanoViricides, Inc. - Novan, Inc. - Novartis AG - Tamir Biotechnology, Inc. - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/pp...ital_warts
BOTA: 1.55 (-0.04), FOMX: 8.71 (+0.07), NNVC: 1.54 (unch), NVS: 79.64 (+0.33)

Global Primary Biliary Cirrhosis Pipeline Review, H2 2015 - 10 Companies & 11 Drug Profiles
M2 - Thu Oct 22, 8:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xvgssb/primary_biliary) has announced the addition of the "Primary Biliary Cirrhosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Primary Biliary Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Primary Biliary Cirrhosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - CymaBay Therapeutics, Inc. - Dr. Falk Pharma GmbH - Enanta Pharmaceuticals, Inc. - GlaxoSmithKline Plc - Intercept Pharmaceuticals, Inc. - Johnson & Johnson - MediGene AG - NGM Biopharmaceuticals, Inc. - Virobay Inc. Drug Profiles - A-4250 - budesonide - FFP-104 - GSK-2330672 - MBX-8025 - NGM-282 - obeticholic acid - RhuDex - Small Molecules to Agonize Farnesoid X Receptor for Non-alcoholic Steatohepatitis and Primary Biliary Cirrhosis - ustekinumab - VBY-825 For more information visit http://www.researchandmarkets.com/research/xv...ry_biliary
JNJ: 119.92 (+0.88), ICPT: 151.59 (-3.37), CBAY: 2.44 (+0.14), VBAY: (), GSK: 43.61 (+0.06), ENTA: 22.44 (+0.06)

Global Germ Cell Tumors Pipeline Review H2 2015 - 8 Companies & 11 Drug Profiles
M2 - Mon Oct 05, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/444kf4/germ_cell_tumors) has announced the addition of the "Germ Cell Tumors - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Germ Cell Tumors, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Germ Cell Tumors and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - ArQule, Inc. - Astex Pharmaceuticals, Inc. - GlaxoSmithKline Plc - MediGene AG - Merck & Co., Inc. - Novartis AG - Philogen S.p.A. - Sanofi Drug Profiles - cabazitaxel - Cell Therapy 1 for Oncology - (dabrafenib mesylate trametinib dimethyl sulfoxide) - G-207 - guadecitabine - pembrolizumab - ribociclib - Small Molecule to Antagonize KIT816 for Aggressive Mastocytosis, Seminoma and AML - Small Molecules to Inhibit Tubulin for Oncology - Tetravil - tivantinib For more information visit http://www.researchandmarkets.com/research/44...ell_tumors
MRK: 63.01 (+0.16), ARQL: 1.45 (unch), GSK: 43.61 (+0.06), NVS: 79.64 (+0.33)

Global Warts Pipeline Review 2015 - 19 Companies & 24 Drug Profiles
M2 - Tue Sep 08, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9xj7l6/warts_pipeline) has announced the addition of the "Warts - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Warts, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Warts and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3M Drug Delivery Systems - Agilvax, Inc. - Biogenomics Limited - BioMAS Ltd. - Biota Pharmaceuticals, Inc. - EpiPharm AG - Foamix Pharmaceuticals Ltd. - G&E Herbal Biotechnology Co., Ltd. - Helix BioPharma Corp. - LEO Pharma A/S - MediGene AG - NanoViricides, Inc. - Nielsen Biosciences, Inc. - Novan, Inc. - Novartis AG - Promius Pharma, LLC - RXi Pharmaceuticals Corporation - Tamir Biotechnology, Inc. - Zydus Cadila Healthcare Limited Drug Profiles - (digoxin furosemide) - 854-A - A-101 - AP-611074 - AS-101 - AX-03 - Candida Albicans Antigen - DFD-05 - diphencyprone - EPI-N06 - HerpeCide-I - human papilloma virus [strains 6,11] (bivalent) vaccine - imiquimod - ingenol mebutate - interferon alfa-2b (recombinant) - interferon alpha-2b (recombinant) - LFX-453 - NVN-1000 - PP-210 - ranpirnase - SB-206 - sinecatechins - SRT-100 - Vaccine for Cervical Cancer and Genital Warts For more information visit http://www.researchandmarkets.com/research/9x...s_pipeline
BOTA: 1.55 (-0.04), FOMX: 8.71 (+0.07), NNVC: 1.54 (unch), NVS: 79.64 (+0.33)

Global Malignant Glioma Pipeline Review 2015
M2 - Tue Sep 08, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ms2wz/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Amgen Inc. - AstraZeneca Plc - BBB Therapeutics B.V. - Eisai Co., Ltd. - Eli Lilly and Company - Genmab A/S - Lipopharma Therapeutics SL - MediGene AG - Nuo Therapeutics, Inc. - Pfizer Inc. - Stemline Therapeutics, Inc. - Tiziana Life Sciences Plc - Vicus Therapeutics, LLC - ZIOPHARM Oncology, Inc. For more information visit http://www.researchandmarkets.com/research/5m...ant_glioma
ZIOP: 5.24 (-0.02), PFE: 35.11 (+0.29), AZN: 33.30 (+0.25), AMGN: 171.51 (-0.46), LLY: 78.60 (+0.36), STML: 8.70 (+0.27)

Global Genital Warts (Condylomata Acuminata) Clinical Trials Review, H1, 2015
M2 - Tue Aug 04, 11:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5dg4t8/genital_warts) has announced the addition of the "Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H1, 2015" report to their offering. Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H1, 2015" provides data on the Genital Warts (Condylomata Acuminata) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Genital Warts (Condylomata Acuminata). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Genital Warts (Condylomata Acuminata). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Genital Warts (Condylomata Acuminata) Therapeutics Clinical Trials - Merck & Co., Inc. - BioMAS Ltd. - Valeant Pharmaceuticals International, Inc. - MediGene AG - Gilead Sciences, Inc. - G&E Herbal Biotechnology Co., Ltd. - Biota Pharmaceuticals, Inc. - Cosmo Pharmaceuticals S.p.A - Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Clinical Trial Overview of Top Institutes / Government - China Medical University - Department of Biotechnology, India - Deutsches Krebsforschungszentrum - Duke University - Huazhong University of Science & Technology - Johannes Gutenberg University Mainz - Kenyatta National Hospital - Medical University of Vienna - Mount Sinai Medical Center - National Cheng-Kung University Hospital For more information visit http://www.researchandmarkets.com/research/5d...ital_warts
GILD: 78.17 (-1.60), BOTA: 1.55 (-0.04), MRK: 63.01 (+0.16), VRX.TO: 39.39 (-0.75)

Vaginal Atrophy (Atrophic Vaginitis) Pipeline Review, H1 2015 - 8 Companies & 8 Drug Profiles
M2 - Thu Jun 25, 6:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/brrxqg/vaginal_atrophy) has announced the addition of the "Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actavis plc - EndoCeutics, Inc. - Foamix Pharmaceuticals Ltd. - MediGene AG - Pantarhei Bioscience BV - Peptonic medical AB - RestorGenex Corporation - TherapeuticsMD Inc. Drug Profiles - esterol - estradiol hemihydrate - oxytocin - prasterone - RES-102 - sinecatechins - TX-004HR - WC-3011 For more information visit http://www.researchandmarkets.com/research/br...al_atrophy
TXMD: 6.73 (-0.16), FOMX: 8.71 (+0.07)

Genital Warts (Condylomata Acuminata) Pipeline Review 2015 - 12 Companies & 14 Drug Profiles
M2 - Wed Jun 24, 10:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tcqv8c/genital_warts) has announced the addition of the "Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Warts (Condylomata Acuminata), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Warts (Condylomata Acuminata) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Agilvax, Inc. - Anaconda Pharma - Biogenomics Limited - BioMAS Ltd. - Foamix Pharmaceuticals Ltd. - G&E Herbal Biotechnology Co., Ltd. - Helix BioPharma Corp. - LEO Pharma A/S - MediGene AG - NanoViricides, Inc. - Novan, Inc. - Tamir Biotechnology, Inc. Drug Profiles - AP-611074 - AS-101 - AX-03 - HerpeCide-I - human papilloma virus [strains 6,11] (bivalent) vaccine - imiquimod - ingenol mebutate - interferon alfa-2b (recombinant) - interferon alpha-2b (recombinant) - PP-210 - ranpirnase - SB-206 - sinecatechins - SRT-100 For more information visit http://www.researchandmarkets.com/research/tc...ital_warts
FOMX: 8.71 (+0.07), NNVC: 1.54 (unch)

T-Cell Leukemia Pipeline Review, H1 2015 - 14 Companies & 20 Drug Profiles
M2 - Thu Jun 11, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2b68lm/tcell_leukemia) has announced the addition of the "T-Cell Leukemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Applied Immune Technologies Ltd - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - iDD biotech SAS - Kyowa Hakko Kirin Co., Ltd. - MediGene AG - Nippon Kayaku Co., Ltd. - Pfizer Inc. - Pharmacyclics, Inc. - Sanofi - Stemline Therapeutics, Inc. - Theravectys S.A. - Tolero Pharmaceuticals, Inc. Drug Profiles - AGS-67E - alemtuzumab - Antibody to Inhibit HLA-A2 for Neurology, Infectious Diseases and T-Cell Leukemia - BMS-906024 - Cell Therapy to Target CD38 for cancer - IDD-003 - INA-01 - lenalidomide - MMIG-202 - mogamulizumab - Monoclonal Antibodies to Antagonize TCR for Leukemia and Autoimmune Disease - Monoclonal Antibody to Target CCR9 for T Lymphoblastic Leukemia - NK-314 - Oncolytic Virus to Target Glycoprotein gp160 for T-cell Leukemia - PCI-34051 - PF-03084014 - SL-101 - Synthetic Peptide for Oncology and Male health - THV-02 - TP-0903 For more information visit http://www.researchandmarkets.com/research/2b...l_leukemia
PCYC: 261.25 (+1.70), PFE: 35.11 (+0.29), BMY: 58.76 (-0.01), STML: 8.70 (+0.27), CELGZ: 1.13 (unch)

Global Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics Development Pipeline Review, H1 2015 - 16 Drug Profiles & 11 Companies
M2 - Fri Jun 05, 8:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wnpg9f/basal_cell) has announced the addition of the "Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - Biofrontera AG - Biogenomics Limited - Biosceptre International Limited - Bristol-Myers Squibb Company - Genextra S.p.a. - MediGene AG - Novartis AG - Oncovir, Inc. - Redx Pharma Ltd - Transgene SA Drug Profiles - aminolevulinic acid hydrochloride - BIL-010t - BMS-833923 - CIGB-128 - CS-S/BCC-1 - CS-TATI-1 - DAC-060 - erismodegib - interferon alfa-2b (recombinant) - LEQ-506 - Oshadi D Oshadi R - Poly-ICLC - sinecatechins - Small Molecule to Inhibit Smoothened Receptor for Basal Cell Carcinoma - Small Molecules to Inhibit Casein Kinase 1 for Cancer - TG-1042 For more information visit http://www.researchandmarkets.com/research/wnpg9f/basal_cell
BMY: 58.76 (-0.01), NVS: 79.64 (+0.33)

Biliary Cirrhosis Therapeutic Pipeline Review H2 2014 Report at ReportsnReports.com
PRWeb - Mon Jan 05, 1:30PM CST
The report "Biliary Cirrhosis - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Biliary Cirrhosis. Primary biliary cirrhosis is a long-term liver disease in which the bile ducts in the liver become damaged. It is most likely an autoimmune disease, where the body's immune system attacks its own cells. It generally strikes women between the ages of 40 and 60. Symptoms of Primary biliary cirrhosis include the following Fatigue, Pruritus, Right upper quadrant discomfort, Hepatomegaly, Hyperpigmentation, Splenomegaly, Jaundice, Xanthelasmata, Sicca syndrome and Kayser-Fleischer rings. Treatment for primary biliary cirrhosis is difficult, because the immune system appears to be involved. Complete Report is Available @ http://www.reportsnreports.com/reports/322822...-2014.html
JNJ: 119.92 (+0.88), SHPG: 190.40 (-0.28), ICPT: 151.59 (-3.37), VBAY: (), GSK: 43.61 (+0.06)

Global Cervical Cancer Therapeutic Pipeline Review, H2 2014 - 35 Companies & 71 Drug Profiles
M2 - Wed Nov 19, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/4p52hn/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - Nektar Therapeutics - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Amorfix Life Sciences Ltd. - MediGene AG - Nanotherapeutics, Inc. - Arbor Vita Corporation - Novartis AG - Chong Kun Dang Pharmaceutical Corp. - Taiho Pharmaceutical Co., Ltd. - Zeria Pharmaceutical Co Ltd - Genmab A/S - Advaxis, Inc. - 3SBio Inc. - Transgene SA - Antigen Express, Inc. - Shantha Biotechnics Limited - Bionor Pharma ASA - Azaya Therapeutics Incorporated - Merrimack Pharmaceuticals, Inc. - Genexine, Inc. - Genticel - Sirnaomics, Inc. - EyeGene, Inc. - Vaccibody AS - Wellstat Biologics Corporation - ISA Pharmaceuticals B.V. For more information visit http://www.researchandmarkets.com/research/4p...cal_cancer
MACK: 4.75 (+0.01), INO: 9.27 (+0.41), ADXS: 11.81 (-0.02), GSK: 43.61 (+0.06), NKTR: 17.32 (-0.11), NVS: 79.64 (+0.33)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tuya Smart: AI Powers New Energy Wave at COP31

Updated Category News Views 0

Tuya Smart's Bold Move at COP31 Tuya Smart, a name you don't want to ignore in the world of energy innovation, made a commanding appearance at COP31. Their message was loud and clear: as the climate gets harsher, they're not just sitting around waiting for the next storm. They're arming households with AI-driven solutions. AI-Powered Energy Management Takes Center Stage...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 51

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 44

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 493

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 326

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 349

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 11

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 187

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 483

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 197

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading

Top 5 Most Recently Viewed Articles

Integer Holdings Opens Conversion on 2.125% Senior Notes

Updated Category News Views 151

Integer Holdings Announces Conversion of Senior Notes Integer Holdings Corporation (NYSE: ITGR) has recently made headlines with the announcement that its 2.125% Convertible Senior Notes, due in 2028, are now eligible for conversion. This pivotal move allows holders to convert their notes into either cash, common stock, or a combination of both. The option to convert is...

Continue Reading
Investors Urged to Consider Class Action Against Micron Technology

Updated Category News Views 119

Class Action Lawsuit Against Micron Technology, Inc. Levi & Korsinsky, LLP has alerted investors in Micron Technology, Inc. (NASDAQ: MU) regarding an ongoing class action securities lawsuit. This legal action aims to represent those investors who may have incurred financial losses during a specified period. Investors are encouraged to stay informed regarding this...

Continue Reading
Expansion Grant from Bradford White Boosts ECA Internship Program

Updated Category News Views 88

Bradford White Fuels Growth in ECA Internship Program Bradford White Corporation, known for its innovative water heating solutions, has committed $50,000 towards expanding the Energy Coordinating Agency's (ECA) internship program focused on heat pump technology. This initiative aims to enhance training opportunities for the next generation of plumbing and HVAC...

Continue Reading
Industrial Automation Market Set for Significant Growth Ahead

Updated Category News Views 199

Transformations in the Industrial Automation Market Landscape The industrial automation sector is undergoing a major shift as manufacturers worldwide increasingly adopt Industry 4.0 technologies and artificial intelligence. This evolution is spurred by pressing challenges including labor shortages and the need for enhanced operational efficiency. The market is projected...

Continue Reading
Exploring Competitive Landscape of Amazon.com in Retail Sector

Updated Category News Views 159

Understanding Amazon.com's Competitive Position In today's dynamic business world, understanding how companies perform against their competitors is essential. This article delves into a detailed examination of Amazon.com (NASDAQ: AMZN) and compares it with key rivals in the broadline retail sector. By exploring crucial financial data, market strategies, and growth...

Continue Reading